Abstract:BackgroundCopper ions are essential for cellular physiology. Cuproptosis is a novel method of copper-dependent cell death, and the cuproptosis-based signature for glioma remains less studied. MethodsSeveral glioma datasets with clinicopathological information were collected from TCGA, GEO and CGGA. Robust Multichip Average (RMA) algorithm was used for background correction and normalization, cuproptosis-related genes (CRGs) were then collected. The TCGA-glioma cohort was clustered using ConsensusClusterPlus. Univariate Cox regression analysis and the Random Survival Forest model were performed on the differentially expressed genes to identify prognostic genes. The cuproptosis-signature was constructed by calculating CuproptosisScore using Multivariate Cox regression analysis. Differences in terms of genomic mutation, tumor microenvironment, and enrichment pathways were evaluated between high- or low-CuproptosisScore. Furthermore, drug response prediction was carried out utilizing pRRophetic. ResultsTwo subclusters based on CRGs were identified. Patients in cluster2 had better clinical outcomes. The cuproptosis-signature was constructed based on CuproptosisScore. Patients with higher CuproptosisScore had higher WHO grades and worse prognosis, while patients with lower grades were more likely to develop IDH mutations or MGMT methylation. Univariate and Multivariate Cox regression analysis demonstrated CuproptosisScore was an independent prognostic factor. The accuracy of the signature in prognostic prediction was further confirmed in 11 external validation datasets. In groups with high-CuproptosisScore, PIK3CA, MUC16, NF1, TTN, TP53, PTEN, and EGFR showed high mutation frequency. IDH1, TP53, ATRX, CIC, and FUBP1 demonstrated high mutation frequency in low-CuproptosisScore group. The level of immune infiltration increased as CuproptosisScore increased. SubMap analysis revealed patients with high-CuproptosisScore may respond to anti-PD-1 therapy. The IC50 values of Bexarotene, Bicalutamide, Bortezomib, and Cytarabine were lower in the high-CuproptosisScore group than those in the low-CuproptosisScore group. Finally, the importance of IGFBP2 in TCGA-glioma cohort was confirmed. ConclusionThe current study revealed the novel cuproptosis-based signature might help predict the prognosis, biological features, and appropriate treatment for patients with glioma.

High expression of COPZ2 is associated with poor prognosis and cancer progression in glioma

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.

DNAJC10 Correlates with Tumor Immune Characteristics and Predicts the Prognosis of Glioma Patients

A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1.

Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients

Downregulation of LUZP2 is Correlated with Poor Prognosis of Low-Grade Glioma

Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines

The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma

Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer

High expression of ZFP36L2 correlates with the prognosis and immune infiltration in lower-grade glioma

Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients

An Integrative Pan-Cancer Analysis of the Oncogenic Role of COPB2 in Human Tumors.

A Pan-Cancer Analysis of the Oncogenic Role of Leucine Zipper Protein 2 in Human Cancer

CKAP2L, as an Independent Risk Factor, Closely Related to the Prognosis of Glioma

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas

Elevated GAS2L3 Expression Correlates with Poor Prognosis in Patients with Glioma: A Study Based on Bioinformatics and Immunohistochemical Analysis

Upregulation of IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression That Is Related to Cell Proliferation, Metastasis and Tumor-Infiltrating Immune Cells

Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma

Prognostic Value of Cuproptosis-Related Genes Signature and Its Impact on the Reshaped Immune Microenvironment of Glioma

High Expression of C1ORF112 Predicts a Poor Outcome: A Potential Target for the Treatment of Low-Grade Gliomas

The expression and clinical significance of HOXB2 in gliomas